Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
This article was originally published in PharmAsia News
The Indian health minister Anbumani Ramadoss urged Novartis earlier this month to end its legal bid to win patent protection for its oncologic Gleevec, or he said the government may override existing patents for vitally necessary drugs by issuing licenses that allow Indian generic manufacturers to produce cheaper versions in the interest of public health
You may also be interested in...
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.
Intellectual Property In India: Novartis Sees Patent Protections To Be In Patients’ Best Interests (Part 3 of 3)
Novartis’ Gleevec patent battle in India has caught the attention of at least one U.S. lawmaker. Meanwhile, the outcome could impact Indian pharmas.
Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)
Novartis argues India’s interpretation of the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights agreement is too strict and focuses too much on efficacy to the exclusion of bioavailability.